As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment from the company’s Japanese partner. ATX-101, a configuration of sodium ion channel blocker bupivacaine and a biopolymer, which is in a phase IIb registration study, is designed to offer pain relief following total knee arthroplasty.
A new version of a drug candidate that failed in a phase II for neuropathic pain 15 years ago has attracted $140 million in series D funds, plus an ex-North American deal worth up to $570 million, for Grin Therapeutics Inc.
Vivace Therapeutics Inc. closed a $35 million series D round led by RA Capital Management, an existing investor, and including other backers already on board: Canaan Partners and Cenova Capital. Proceeds will support the continued development of what the company describes as its first-in-class and best-in-class transcriptional enhanced associate domain autopalmitoylation (TEAD) inhibitor, VT-3989, with an initial focus on mesothelioma.
4C Medical Technologies Inc. raised $175 million in a series D financing round led by Boston Scientific Corp. The financing will support the regulatory trials and commercialization of the Altavalve system, a transcatheter mitral valve replacement (TMVR) technology.
With the closing of its $350.7 million series D, Eikon Therapeutics Inc. has notched two financial high marks for the still young year. The funding is the biggest venture capital round of 2025 and it’s also the first series D.
Dexcom Inc. put real money behind expanding its integration efforts, with a $75 million investment in the $200 million series D for Ōura Health Oy, the maker of the Ōura smart ring. Ōura and Dexcom also provided details on a strategic partnership that integrates data from Dexcom’s continuous glucose monitors with vital sign, sleep, stress, heart health and activity data from the Ōura ring.
Alentis Therapeutics SA is poised to expand its reach in Claudin-1 biology, after closing a $181.4 million series D that will fund phase I/II trials of two antibody-drug conjugates (ADCs) targeting the transmembrane protein, which is overexpressed on a number of squamous cell tumors.
The $80 million in financing that Huma Therapeutics Ltd. recently raised is a testament to where the company is and what it achieved at a time when the digital health industry is struggling to raise significant financing, Mert Aral, chief medical officer at Huma, told BioWorld.
Tricares SAS raised $50 million in a series D financing round to support upcoming clinical trials in the U.S. and EU for its transfemoral tricuspid heart valve replacement system, Topaz.
Catalym GmbH has closed a $150 million series D to take its first in class immune potentiator visugromab into phase IIb development in a number of solid tumors. The round follows on the heels of data from a phase I/IIa trial which showed visugromab in combination with the PD-1 inhibitor antibody Opdivo (nivolumab, Bristol Myers Squibb) increased T-cell infiltration and generated durable antitumor responses in patients who had exhausted all other treatment options.
RSS
